Drug Type Small molecule drug |
Synonyms SL 901 |
Target |
Action inhibitors |
Mechanism PI3K family inhibitors(Phosphatidylinositol 3-kinase family inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Solid tumor | Phase 1 | Italy | 30 Jan 2022 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | United Kingdom | 19 Mar 2021 | |
| Lung Cancer | Phase 1 | - | - |
Phase 1 | 20 | (Cohort 1: SL-901 20 mg) | vvvdmofkln = mvwlvagihl usfcysydon (extnrhtiix, qyzufxylew - eharjwxyko) View more | - | 09 Jan 2025 | ||
(Cohort 2: SL-901 40 mg) | vvvdmofkln = ttyjzpuavo usfcysydon (extnrhtiix, qwlcxvdocv - xrqzlgkxpr) View more |





